A retrospective study to determine safety and efficacy of 177Lu-DOTATATE in older patients with advanced neuroendocrine tumours
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2021 New trial record
- 01 Oct 2021 Results published in the European Journal of Nuclear Medicine and Molecular Imaging